Equity Details
Price & Market Data
Price: $5.48
Daily Change: -$0.579 / 10.57%
Daily Range: $5.34 - $5.97
Market Cap: $3,112,709
Daily Volume: 16,066
Performance Metrics
1 Week: -21.42%
1 Month: 77.16%
3 Months: -8.72%
6 Months: -78.06%
1 Year: -91.84%
YTD: -55.64%
About SciSparc Ltd. (SPRC)
Quick facts and data for SciSparc Ltd. (SPRC). Price: 5.48, daily change: -$0.579 / 10.57%. Market cap: 3,112,709. Performance across all periods.
Company Details
Employees: 2
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.